Literature DB >> 19017783

The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.

Luca Rozzini1, Barbara Vicini Chilovi, Erik Bertoletti, Marta Conti, Ilenia Delrio, Marco Trabucchi, Alessandro Padovani.   

Abstract

The aim of this study was to verify the usefulness of Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-Cog), in screening participants at risk of developing Alzheimer disease (AD) among populations with amnestic mild cognitive impairment(aMCI). 98 outpatients with aMCI were recruited. Participants were revaluated after 1 year: 44 (44.9%) were progressed to AD (progressors), while 54 (55.1%) did not convert (nonprogressors MCI). At baseline, cognitive performances were more impaired in progressors assessed by MMSE and by a neuropsychological battery. When tested with the ADAS-Cog subscale, the 2 groups of participants at baseline, progressors, and nonprogressors MCI, were significantly different regarding total score, memory, and nonmemory subitems. Considering a cutoff of 9.5 total score, adjusted for education, ADAS-Cog subscale showed a good performance (area under the curve = 0.67; sensitivity = 0.62%; specificity = 0.73%) in predicting conversion from aMCI to AD. Progressors aMCI were characterized at baseline by a greater cognitive impairment. ADAS-Cog subscale is a useful and brief cognitive assessment tool to screen aMCI participants converting to AD within 1 year.

Entities:  

Mesh:

Year:  2008        PMID: 19017783     DOI: 10.1177/0891988708324940

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  3 in total

1.  Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods.

Authors:  Robert M Chapman; Mark Mapstone; John W McCrary; Margaret N Gardner; Anton Porsteinsson; Tiffany C Sandoval; Maria D Guillily; Elizabeth Degrush; Lindsey A Reilly
Journal:  J Clin Exp Neuropsychol       Date:  2010-08-13       Impact factor: 2.475

2.  At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction.

Authors:  Paolo Fusar-Poli; Marco Cappucciati; Grazia Rutigliano; Frauke Schultze-Lutter; Ilaria Bonoldi; Stefan Borgwardt; Anita Riecher-Rössler; Jean Addington; Diana Perkins; Scott W Woods; Thomas H McGlashan; Jimmy Lee; Joachim Klosterkötter; Alison R Yung; Philip McGuire
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

3.  Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study.

Authors:  Danilo Zanotta; Silvana Puricelli; Guido Bonoldi
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-03       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.